Oncology leaders use real-world evidence to help curb a lack of diversity in clinical trials
21 April 2021
- One issue that leads to disparities between trial populations and the general population is the use of stringent eligibility criteria in clinical trials. Real-world patients may have comorbidities and other traits that can lead to their exclusion from cancer trials that are designed for maximum clarity of data
- The FDA’s 2018 Drug Trials Snapshots showed that of the more than 5000 patients that year who participated in oncology trials that led to approvals, just 4% were Black and 4% were Hispanic, despite the fact that 13.4% of the US population was Black and 18.1% was Hispanic
- Women were also under-represented: They made up 38% of the trial population but 51% of the US population. At the same time, Asian patients were overrepresented, making up 15% of the trial population but just 5.8% of the US population
Click here to learn more.
SVMPharma is an innovative strategic consultancy, specialising in Real-World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real-World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.
For more information, please visit www.svmpharma.com and contact us at email@example.com